Document detail
ID

doi:10.1038/s42003-023-04793-3...

Author
Dzimianski, John V. Han, Julianna Sautto, Giuseppe A. O’Rourke, Sara M. Cruz, Joseph M. Pierce, Spencer R. Ecker, Jeffrey W. Carlock, Michael A. Nagashima, Kaito A. Mousa, Jarrod J. Ross, Ted M. Ward, Andrew B. DuBois, Rebecca M.
Langue
en
Editor

Nature

Category

Life Sciences

Year

2023

listing date

4/26/2023

Keywords
computationally influenza vaccine hemagglutinin optimized cobra
Metrics

Abstract

Structural studies of a computationally optimized broadly reactive antigen hemagglutinin in complex with a broadly neutralizing antibody reveal its immunogenic properties and provide insights into flu vaccine design.

Influenza virus poses an ongoing human health threat with pandemic potential.

Due to mutations in circulating strains, formulating effective vaccines remains a challenge.

The use of computationally optimized broadly reactive antigen (COBRA) hemagglutinin (HA) proteins is a promising vaccine strategy to protect against a wide range of current and future influenza viruses.

Though effective in preclinical studies, the mechanistic basis driving the broad reactivity of COBRA proteins remains to be elucidated.

Here, we report the crystal structure of the COBRA HA termed P1 and identify antigenic and glycosylation properties that contribute to its immunogenicity.

We further report the cryo-EM structure of the P1-elicited broadly neutralizing antibody 1F8 bound to COBRA P1, revealing 1F8 to recognize an atypical receptor binding site epitope via an unexpected mode of binding.

Dzimianski, John V.,Han, Julianna,Sautto, Giuseppe A.,O’Rourke, Sara M.,Cruz, Joseph M.,Pierce, Spencer R.,Ecker, Jeffrey W.,Carlock, Michael A.,Nagashima, Kaito A.,Mousa, Jarrod J.,Ross, Ted M.,Ward, Andrew B.,DuBois, Rebecca M., 2023, Structural insights into the broad protection against H1 influenza viruses by a computationally optimized hemagglutinin vaccine, Nature

Document

Open

Share

Source

Articles recommended by ES/IODE AI

Systematic druggable genome-wide Mendelian randomization identifies therapeutic targets for lung cancer
agphd1 subtypes replication hykk squamous cell gene carcinoma causal targets mendelian randomization cancer analysis